Please assess the completion status of the following clinical trial:

Trial Title: Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lower extremity full thickness venous ulcer of \> 30 days duration~* Subject's wound must be between 4 cm² and 50 cm² at screening~* Documented ABI that is between 0.8 and 1.2 on the study limb or transcutaneous partial pressure oxygen (TcpO2) \> 40 mmHG; or a toe pressure \> 40 mmHG; or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic waveforms) at time of screening~* Biopsy for wounds \> 6 months duration~* Documented index wound etiology of venous stasis with reflux and /or incompetent valves~Exclusion Criteria:~* Index ulcer wound that is less than 1 cm in distance from another ulcer wound~* \> 5 ulcers on the index leg~* Index ulcer wound has exposed tendons, ligaments, muscle, or bone~* Index ulcer wound presents with clinical signs of acute infection, suspected or known~* Subjects with evidence of osteomyelitis or cellulitis or gangrene in the study limb~* Subjects with amputation above a Trans Metatarsal Amputation (TMA) in the study limb~* Subjects with active malignancy on the study limb except non-melanoma skin cancer~* Index ulcer that is of arterial disease etiology~* Index ulcer of other primary etiology (ie. vasculitis, arterial, pyoderma)~* Subjects with planned vascular surgery, angioplasty or thrombolysis procedures within the study treatment phase~* Subjects with planned surgical procedure during the study treatment phase for the index wound including skin flap or skin graft~* Subjects within 6 weeks postoperatively of a vascular o skin graft procedure.~* Subject has had prior skin replacement, negative pressure therapy, or traditional ultrasound therapy applied to the index wound in the 14 days prior to screening~* Subject has had ultrasound treatment (including MIST Therapy) of the index wound.~* Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within 14 days of screening date.~* Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.~* Female subjects that are pregnant or refuse to utilize adequate contraceptive methods and are of childbearing age during the trial.~* Subject has one or more medical condition(s), uncontrolled diabetes (i.e. HbA1c \> 12), renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the subject an inappropriate study candidate~* Subject's wound would require ultrasound near an electronic implant or prosthesis~* Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements~* Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): 30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
- SOC + Mist Therapy (Type: EXPERIMENTAL): 30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).